As of 10:20 on March 20, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 0.28%, the constituent shares Chi-Med (00013) rose 6.28%, Hansoh Pharmaceuticals (03692) rose 2.38%, BeiGene (06160) rose 2.00%, Keynova-B (02162) rose 1.64%, and CSPC Pharmaceutical Group (01093) rose 1.39%. Hong Kong stock pharmaceutical ETF (159718) once rose nearly 1%, hitting three consecutive gains. The latest price was reported at 0.72 yuan, and the intraday turnover had reached 15.2994 million yuan, with a turnover rate of 6.78%.

As of 10:21 on March 20, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) fell by 0.38%. In terms of constituent stocks, Yirui Technology (688301) led the rise by 3.18%, Haisco (002653) rose 1.49%, and Tebao Biotechnology (688278) rose 0.72%; Hengrui Pharmaceutical (600276) led the decline by 1.29%, Huitai Medical (688617) fell by 1.18%, and Baili Tianheng (688506) fell by 1.11%. Medical Innovation ETF (516820) fell 0.57%, the latest price was 0.35 yuan, and the intraday turnover has reached 11.3377 million yuan.

In the long run, as of March 19, 2025, Hong Kong stock pharmaceutical ETFs have risen by 6.98% in the past 1 week, ranking 1/4 of comparable funds. Medical Innovation ETF has risen by 3.54% over the past 1 week.

In terms of scale, the latest scale of medical innovation ETF reached 1.797 billion yuan. In terms of capital inflow, the medical innovation ETF has attracted a total of 15.5789 million yuan in the past 20 trading days.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 4.5537 million yuan, and the latest financing balance reached 83.288 million yuan.

On the news side, in the past year, the number of new drug marketing applications approved by the State Food and Drug Administration has maintained growth, and the number of Class 1 new drugs approved has reached a new high, reaching 48. These 48 varieties include a number of domestic new drugs that have made breakthroughs in cutting-edge targets, imported new drugs that have been developed and declared simultaneously in the world and launched for the first time in China, and drugs for the treatment of Alzheimer's disease. Among them, domestic Class 1 new drugs accounted for more than 70%, and nearly 40% were included in the basic medical insurance in the year of listing.

Recently, Guangdong Province issued the "Implementation Plan of Guangdong Province to Promote the High-quality Development of the Silver Economy and Enhance the Well-being of the Elderly", supporting social forces to set up medical and elderly care institutions, and strengthening the construction of rehabilitation hospitals, nursing institutions and palliative care institutions. By 2027, more than 85% of general hospitals at level 2 and above will have geriatric departments.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.